IDH1 mutations have been shown to improve LGG prognosis and lower-grade gliomas that had mutations in IDH but did not have 1p/19q codeletion virtually always also had mutations in ATRX inactivation (86%) and TP53 (94%) (Cancer Genome Atlas Research et al., 2015). Here, ATRX is linked to central nervous system cancer.